drugset / Trial / NCT05962788

Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05962788

Phase 3 Terminated 4 enrolled Aurinia Pharmaceuticals Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long-term safety and tolerability of voclosporin for up to an additional 12 months following completion of treatment in the AUR-VCS-2020-03 study (VOCAL) in adolescent and pediatric subjects with lupus nephritis.

Timeline

Start
2024-03-28
Primary completion
2025-07-04
Completion
2025-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Voclosporin Other / unclassified 15.8 mg
Subject Voclosporin Other / unclassified 23.7 mg

Indications